Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial (EnACT)

NCT04031833 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

178

Enrollment

INDUSTRY

Sponsor class

Conditions

Cryptococcal Meningitis

Interventions

DRUG: MAT2203
DRUG: Amphotericin B

Sponsor

Matinas BioPharma Nanotechnologies, Inc.

Collaborators

[object Object]